Anciata Therapeutics

Anciata Therapeutics is a special purpose company aimed at developing IPX-2017, a novel oral therapy for the treatment of autoimmune diseases with clinical proof-of-concept. Anciata Therapeutics is fully funded by TVM Life Science Innovation II and led by an experienced management team.